scispace - formally typeset
Journal ArticleDOI

Hepatitis B virus infection.

William M. Lee
- 11 Dec 1997 - 
- Vol. 337, Iss: 24, pp 1733-1745
TLDR
This review addresses many aspects of HBV infection, including the role of the immune system in determining the outcome of clinical infection, recent developments in molecular studies of the virus, and new treatments capable of eradicating chronic infection.
Abstract
The hepatitis B virus (HBV), discovered in 1966, infects more than 350 million people worldwide.1 Hepatitis B is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma, accounting for 1 million deaths annually. Knowledge of the intricacies of viral infection and of the molecular biology of this fascinating virus has led to the successful development of a vaccine and to treatment sometimes capable of eradicating chronic infection. This review addresses many aspects of HBV infection, including the role of the immune system in determining the outcome of clinical infection, recent developments in molecular studies of the virus, and new . . .

read more

Citations
More filters
Journal ArticleDOI

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.
Journal ArticleDOI

Chronic hepatitis B

TL;DR: These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV).
Journal ArticleDOI

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

TL;DR: More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV‐related morbidity and mortality.
Journal ArticleDOI

Viral hepatitis B

TL;DR: Current available monotherapies-interferon, lamivudine, and adefovir dipivoxil-very rarely eradicate the virus, but greatly reduce its replication, necroinflammatory histological activity, and progression of fibrosis.
References
More filters
Journal ArticleDOI

HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS. A Prospective Study of 22 707 Men in Taiwan

TL;DR: A prospective general population study of 22 707 Chinese men in Taiwan has shown that the incidence of primary hepatocellular carcinoma (PHC) among carriers of hepatitis B surface antigen (HBsAg) is much higher than among non-carriers as discussed by the authors.
Journal ArticleDOI

A One-Year Trial of Lamivudine for Chronic Hepatitis B

TL;DR: In a one-year study, lamivudine was associated with substantial histologic improvement in many patients with chronic hepatitis B, and a daily dose of 100 mg was more effective than a daily doses of 25 mg.
Journal ArticleDOI

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.

TL;DR: The incidence of hepatocellular carcinoma in children in Taiwan from 1981 to 1994 has declined since the institution of Taiwan's program of universal hepatitis B vaccination, and the corresponding rates of mortality have decreased.
Journal ArticleDOI

A role for hepatitis C virus infection in type II cryoglobulinemia.

TL;DR: Type II cryoglobulinemia is strongly associated with concomitant HCV infection and a high rate of false negative serologic tests, suggesting a role for HCV in the pathogenesis of mixed cryoglOBulinemi.
Journal ArticleDOI

Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.

TL;DR: A meta-analysis of randomized, controlled trials was conducted to examine the efficacy of interferon treatment in patients with chronic HBV infection as determined by the loss of HBsAg, HBeAg, and HBV DNA.
Related Papers (5)